Loading…

Vancomycin powder in the prevention of infection in primary knee and hip arthroplasty: Case-control study with 1151 arthroplasties

Vancomycin powder (VP) has been positively used in spinal surgery to reduce the rate of infections. Hardly any data have been published on hip and knee joint replacement surgery, and its usefulness is questioned. Our objective was to investigate the effectiveness of VP in reducing prosthetic infecti...

Full description

Saved in:
Bibliographic Details
Published in:Revista española de cirugía ortopédica y traumatología 2024-07, Vol.68 (4), p.344
Main Authors: Paredes-Carnero, X, Vidal-Campos, J, Gómez-Suárez, F, Meijide, H
Format: Article
Language:eng ; spa
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue 4
container_start_page 344
container_title Revista española de cirugía ortopédica y traumatología
container_volume 68
creator Paredes-Carnero, X
Vidal-Campos, J
Gómez-Suárez, F
Meijide, H
description Vancomycin powder (VP) has been positively used in spinal surgery to reduce the rate of infections. Hardly any data have been published on hip and knee joint replacement surgery, and its usefulness is questioned. Our objective was to investigate the effectiveness of VP in reducing prosthetic infection and its possible complications.BACKGROUND AND OBJECTIVEVancomycin powder (VP) has been positively used in spinal surgery to reduce the rate of infections. Hardly any data have been published on hip and knee joint replacement surgery, and its usefulness is questioned. Our objective was to investigate the effectiveness of VP in reducing prosthetic infection and its possible complications.Primary hip (THA) and knee (TKA) arthroplasties were reviewed, performed by five surgeons in one hospital center, between 2017 and 2018. 1g of VP was used on the implant prior to surgical closure based on the surgeon's preferences. With a 5-year follow-up in which the infection rate and local complications were analyzed.METHODSPrimary hip (THA) and knee (TKA) arthroplasties were reviewed, performed by five surgeons in one hospital center, between 2017 and 2018. 1g of VP was used on the implant prior to surgical closure based on the surgeon's preferences. With a 5-year follow-up in which the infection rate and local complications were analyzed.One thousand one hundred and fifty one arthroplasties were performed, 748 were TKA and 403 were THA. Nine patients were diagnosed with prosthetic infection, of which five received VP and four did not (P=.555). Likewise, another 15 patients suffered wound complications, of which 11 received VP and 4 did not (P=.412). There were no differences, either, in the rest of the complications depending on the use or not of VP (P=.101). Likewise, the number of patients who needed reintervention was similar (P=.999). No systemic complications were detected due to the use of VP.RESULTSOne thousand one hundred and fifty one arthroplasties were performed, 748 were TKA and 403 were THA. Nine patients were diagnosed with prosthetic infection, of which five received VP and four did not (P=.555). Likewise, another 15 patients suffered wound complications, of which 11 received VP and 4 did not (P=.412). There were no differences, either, in the rest of the complications depending on the use or not of VP (P=.101). Likewise, the number of patients who needed reintervention was similar (P=.999). No systemic complications were detected due to the use of VP.It has
doi_str_mv 10.1016/j.recot.2023.12.003
format article
fullrecord <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_miscellaneous_2905782935</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2905782935</sourcerecordid><originalsourceid>FETCH-LOGICAL-p103t-59571fd8ec860ef517f6a59e419e5a6cb1ba98cd368a471d6349763cda02eec13</originalsourceid><addsrcrecordid>eNpNjz1PwzAYhC0EEqXwC1g8siT4jWvHZkMVX1IlFmCtXOeN4pLawXapsvLLKR9Dp3vudDrpCLkEVgIDeb0uI9qQy4pVvISqZIwfkQlopQqlhDw-4FNyltKaMTkDDRPy9Wa8DZvROk-HsGsw0j3lDukQ8RN9dsHT0O7DFu2v-SlGtzFxpO8ekRrf0M4N1MTcxTD0JuXxhs5NwsIGn2PoacrbZqQ7lzsKIOCw6jCdk5PW9Akv_nVKXu_vXuaPxeL54Wl-uygGYDwXQosa2kahVZJhK6BupREa9z9QGGlXsDJa2YZLZWY1NJLPdC25bQyrEC3wKbn62x1i-NhiysuNSxb73ngM27SsNBO1qjQX_BunC2f-</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2905782935</pqid></control><display><type>article</type><title>Vancomycin powder in the prevention of infection in primary knee and hip arthroplasty: Case-control study with 1151 arthroplasties</title><source>ScienceDirect Freedom Collection 2022-2024</source><source>ScienceDirect Journals</source><creator>Paredes-Carnero, X ; Vidal-Campos, J ; Gómez-Suárez, F ; Meijide, H</creator><creatorcontrib>Paredes-Carnero, X ; Vidal-Campos, J ; Gómez-Suárez, F ; Meijide, H</creatorcontrib><description>Vancomycin powder (VP) has been positively used in spinal surgery to reduce the rate of infections. Hardly any data have been published on hip and knee joint replacement surgery, and its usefulness is questioned. Our objective was to investigate the effectiveness of VP in reducing prosthetic infection and its possible complications.BACKGROUND AND OBJECTIVEVancomycin powder (VP) has been positively used in spinal surgery to reduce the rate of infections. Hardly any data have been published on hip and knee joint replacement surgery, and its usefulness is questioned. Our objective was to investigate the effectiveness of VP in reducing prosthetic infection and its possible complications.Primary hip (THA) and knee (TKA) arthroplasties were reviewed, performed by five surgeons in one hospital center, between 2017 and 2018. 1g of VP was used on the implant prior to surgical closure based on the surgeon's preferences. With a 5-year follow-up in which the infection rate and local complications were analyzed.METHODSPrimary hip (THA) and knee (TKA) arthroplasties were reviewed, performed by five surgeons in one hospital center, between 2017 and 2018. 1g of VP was used on the implant prior to surgical closure based on the surgeon's preferences. With a 5-year follow-up in which the infection rate and local complications were analyzed.One thousand one hundred and fifty one arthroplasties were performed, 748 were TKA and 403 were THA. Nine patients were diagnosed with prosthetic infection, of which five received VP and four did not (P=.555). Likewise, another 15 patients suffered wound complications, of which 11 received VP and 4 did not (P=.412). There were no differences, either, in the rest of the complications depending on the use or not of VP (P=.101). Likewise, the number of patients who needed reintervention was similar (P=.999). No systemic complications were detected due to the use of VP.RESULTSOne thousand one hundred and fifty one arthroplasties were performed, 748 were TKA and 403 were THA. Nine patients were diagnosed with prosthetic infection, of which five received VP and four did not (P=.555). Likewise, another 15 patients suffered wound complications, of which 11 received VP and 4 did not (P=.412). There were no differences, either, in the rest of the complications depending on the use or not of VP (P=.101). Likewise, the number of patients who needed reintervention was similar (P=.999). No systemic complications were detected due to the use of VP.It has not been possible to demonstrate that the use of VP reduces the rates of prosthetic infection in the hip and knee, so we cannot recommend its use.CONCLUSIONSIt has not been possible to demonstrate that the use of VP reduces the rates of prosthetic infection in the hip and knee, so we cannot recommend its use.</description><identifier>ISSN: 1988-8856</identifier><identifier>EISSN: 1988-8856</identifier><identifier>DOI: 10.1016/j.recot.2023.12.003</identifier><language>eng ; spa</language><ispartof>Revista española de cirugía ortopédica y traumatología, 2024-07, Vol.68 (4), p.344</ispartof><rights>Copyright © 2023 SECOT. Publicado por Elsevier España, S.L.U. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Paredes-Carnero, X</creatorcontrib><creatorcontrib>Vidal-Campos, J</creatorcontrib><creatorcontrib>Gómez-Suárez, F</creatorcontrib><creatorcontrib>Meijide, H</creatorcontrib><title>Vancomycin powder in the prevention of infection in primary knee and hip arthroplasty: Case-control study with 1151 arthroplasties</title><title>Revista española de cirugía ortopédica y traumatología</title><description>Vancomycin powder (VP) has been positively used in spinal surgery to reduce the rate of infections. Hardly any data have been published on hip and knee joint replacement surgery, and its usefulness is questioned. Our objective was to investigate the effectiveness of VP in reducing prosthetic infection and its possible complications.BACKGROUND AND OBJECTIVEVancomycin powder (VP) has been positively used in spinal surgery to reduce the rate of infections. Hardly any data have been published on hip and knee joint replacement surgery, and its usefulness is questioned. Our objective was to investigate the effectiveness of VP in reducing prosthetic infection and its possible complications.Primary hip (THA) and knee (TKA) arthroplasties were reviewed, performed by five surgeons in one hospital center, between 2017 and 2018. 1g of VP was used on the implant prior to surgical closure based on the surgeon's preferences. With a 5-year follow-up in which the infection rate and local complications were analyzed.METHODSPrimary hip (THA) and knee (TKA) arthroplasties were reviewed, performed by five surgeons in one hospital center, between 2017 and 2018. 1g of VP was used on the implant prior to surgical closure based on the surgeon's preferences. With a 5-year follow-up in which the infection rate and local complications were analyzed.One thousand one hundred and fifty one arthroplasties were performed, 748 were TKA and 403 were THA. Nine patients were diagnosed with prosthetic infection, of which five received VP and four did not (P=.555). Likewise, another 15 patients suffered wound complications, of which 11 received VP and 4 did not (P=.412). There were no differences, either, in the rest of the complications depending on the use or not of VP (P=.101). Likewise, the number of patients who needed reintervention was similar (P=.999). No systemic complications were detected due to the use of VP.RESULTSOne thousand one hundred and fifty one arthroplasties were performed, 748 were TKA and 403 were THA. Nine patients were diagnosed with prosthetic infection, of which five received VP and four did not (P=.555). Likewise, another 15 patients suffered wound complications, of which 11 received VP and 4 did not (P=.412). There were no differences, either, in the rest of the complications depending on the use or not of VP (P=.101). Likewise, the number of patients who needed reintervention was similar (P=.999). No systemic complications were detected due to the use of VP.It has not been possible to demonstrate that the use of VP reduces the rates of prosthetic infection in the hip and knee, so we cannot recommend its use.CONCLUSIONSIt has not been possible to demonstrate that the use of VP reduces the rates of prosthetic infection in the hip and knee, so we cannot recommend its use.</description><issn>1988-8856</issn><issn>1988-8856</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpNjz1PwzAYhC0EEqXwC1g8siT4jWvHZkMVX1IlFmCtXOeN4pLawXapsvLLKR9Dp3vudDrpCLkEVgIDeb0uI9qQy4pVvISqZIwfkQlopQqlhDw-4FNyltKaMTkDDRPy9Wa8DZvROk-HsGsw0j3lDukQ8RN9dsHT0O7DFu2v-SlGtzFxpO8ekRrf0M4N1MTcxTD0JuXxhs5NwsIGn2PoacrbZqQ7lzsKIOCw6jCdk5PW9Akv_nVKXu_vXuaPxeL54Wl-uygGYDwXQosa2kahVZJhK6BupREa9z9QGGlXsDJa2YZLZWY1NJLPdC25bQyrEC3wKbn62x1i-NhiysuNSxb73ngM27SsNBO1qjQX_BunC2f-</recordid><startdate>20240701</startdate><enddate>20240701</enddate><creator>Paredes-Carnero, X</creator><creator>Vidal-Campos, J</creator><creator>Gómez-Suárez, F</creator><creator>Meijide, H</creator><scope>7X8</scope></search><sort><creationdate>20240701</creationdate><title>Vancomycin powder in the prevention of infection in primary knee and hip arthroplasty: Case-control study with 1151 arthroplasties</title><author>Paredes-Carnero, X ; Vidal-Campos, J ; Gómez-Suárez, F ; Meijide, H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p103t-59571fd8ec860ef517f6a59e419e5a6cb1ba98cd368a471d6349763cda02eec13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng ; spa</language><creationdate>2024</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paredes-Carnero, X</creatorcontrib><creatorcontrib>Vidal-Campos, J</creatorcontrib><creatorcontrib>Gómez-Suárez, F</creatorcontrib><creatorcontrib>Meijide, H</creatorcontrib><collection>MEDLINE - Academic</collection><jtitle>Revista española de cirugía ortopédica y traumatología</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paredes-Carnero, X</au><au>Vidal-Campos, J</au><au>Gómez-Suárez, F</au><au>Meijide, H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Vancomycin powder in the prevention of infection in primary knee and hip arthroplasty: Case-control study with 1151 arthroplasties</atitle><jtitle>Revista española de cirugía ortopédica y traumatología</jtitle><date>2024-07-01</date><risdate>2024</risdate><volume>68</volume><issue>4</issue><spage>344</spage><pages>344-</pages><issn>1988-8856</issn><eissn>1988-8856</eissn><abstract>Vancomycin powder (VP) has been positively used in spinal surgery to reduce the rate of infections. Hardly any data have been published on hip and knee joint replacement surgery, and its usefulness is questioned. Our objective was to investigate the effectiveness of VP in reducing prosthetic infection and its possible complications.BACKGROUND AND OBJECTIVEVancomycin powder (VP) has been positively used in spinal surgery to reduce the rate of infections. Hardly any data have been published on hip and knee joint replacement surgery, and its usefulness is questioned. Our objective was to investigate the effectiveness of VP in reducing prosthetic infection and its possible complications.Primary hip (THA) and knee (TKA) arthroplasties were reviewed, performed by five surgeons in one hospital center, between 2017 and 2018. 1g of VP was used on the implant prior to surgical closure based on the surgeon's preferences. With a 5-year follow-up in which the infection rate and local complications were analyzed.METHODSPrimary hip (THA) and knee (TKA) arthroplasties were reviewed, performed by five surgeons in one hospital center, between 2017 and 2018. 1g of VP was used on the implant prior to surgical closure based on the surgeon's preferences. With a 5-year follow-up in which the infection rate and local complications were analyzed.One thousand one hundred and fifty one arthroplasties were performed, 748 were TKA and 403 were THA. Nine patients were diagnosed with prosthetic infection, of which five received VP and four did not (P=.555). Likewise, another 15 patients suffered wound complications, of which 11 received VP and 4 did not (P=.412). There were no differences, either, in the rest of the complications depending on the use or not of VP (P=.101). Likewise, the number of patients who needed reintervention was similar (P=.999). No systemic complications were detected due to the use of VP.RESULTSOne thousand one hundred and fifty one arthroplasties were performed, 748 were TKA and 403 were THA. Nine patients were diagnosed with prosthetic infection, of which five received VP and four did not (P=.555). Likewise, another 15 patients suffered wound complications, of which 11 received VP and 4 did not (P=.412). There were no differences, either, in the rest of the complications depending on the use or not of VP (P=.101). Likewise, the number of patients who needed reintervention was similar (P=.999). No systemic complications were detected due to the use of VP.It has not been possible to demonstrate that the use of VP reduces the rates of prosthetic infection in the hip and knee, so we cannot recommend its use.CONCLUSIONSIt has not been possible to demonstrate that the use of VP reduces the rates of prosthetic infection in the hip and knee, so we cannot recommend its use.</abstract><doi>10.1016/j.recot.2023.12.003</doi></addata></record>
fulltext fulltext
identifier ISSN: 1988-8856
ispartof Revista española de cirugía ortopédica y traumatología, 2024-07, Vol.68 (4), p.344
issn 1988-8856
1988-8856
language eng ; spa
recordid cdi_proquest_miscellaneous_2905782935
source ScienceDirect Freedom Collection 2022-2024; ScienceDirect Journals
title Vancomycin powder in the prevention of infection in primary knee and hip arthroplasty: Case-control study with 1151 arthroplasties
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T11%3A03%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Vancomycin%20powder%20in%20the%20prevention%20of%20infection%20in%20primary%20knee%20and%20hip%20arthroplasty:%20Case-control%20study%20with%201151%20arthroplasties&rft.jtitle=Revista%20espa%C3%B1ola%20de%20cirug%C3%ADa%20ortop%C3%A9dica%20y%20traumatolog%C3%ADa&rft.au=Paredes-Carnero,%20X&rft.date=2024-07-01&rft.volume=68&rft.issue=4&rft.spage=344&rft.pages=344-&rft.issn=1988-8856&rft.eissn=1988-8856&rft_id=info:doi/10.1016/j.recot.2023.12.003&rft_dat=%3Cproquest%3E2905782935%3C/proquest%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-p103t-59571fd8ec860ef517f6a59e419e5a6cb1ba98cd368a471d6349763cda02eec13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2905782935&rft_id=info:pmid/&rfr_iscdi=true